SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan ...Middle East

PR Newswire - News
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused...

Hence then, the article about sonire announces first patient enrolled in randomized phase 2 study of its novel hifu therapy system for unresectable pancreatic cancer patients in japan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan )

Apple Storegoogle play

Last updated :

Also on site :